Subclinical gut inflammation in ankylosing spondylitis

@article{Ciccia2016SubclinicalGI,
  title={Subclinical gut inflammation in ankylosing spondylitis},
  author={Francesco Ciccia and Aroldo Gabriele Rizzo and Giovanni Triolo},
  journal={Current Opinion in Rheumatology},
  year={2016},
  volume={28},
  pages={89–96}
}
Purpose of reviewSubclinical gut inflammation has been described in a significant proportion of patients with ankylosing spondylitis (AS), up to 10% of them developing it during the time of clinically overt inflammatory bowel disease. Histologic, immunologic, and intestinal microbiota alterations characterize the AS gut. Recent findingsMicrobial dysbiosis as well as alterations of innate immune responses have been demonstrated in the gut of AS. Furthermore, a growing body of evidence suggests… Expand
A Possible Role of Intestinal Microbiota in the Pathogenesis of Ankylosing Spondylitis
TLDR
The existing evidence for the involvement of the microbiome in AS pathogenesis was discussed and the potential of intestinal microbiome-targeting strategies in the prevention and treatment of AS was evaluated. Expand
Characteristics of the intestinal microbiome in ankylosing spondylitis
TLDR
The findings support that the intestinal microbiome in AS patients has a special signature characterized by an inflammatory status and numerous environmental, genetical, clinical and paraclinical factors can lead to changes in gut bacterial diversity in these cases. Expand
Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice
TLDR
It is found that rifaximin significantly reduced the severity of AS and resulted in down-regulation of inflammatory factors, such as TNF-α,IL-6, IL-17A, and IL-23, as well as selectively promoting some probiotic populations, including Lactobacillales. Expand
Recent advances in ankylosing spondylitis: understanding the disease and management
TLDR
The latest therapies for spondyloarthritis and the most relevant discoveries over the last three years, together with their implications for different aspects of the disease are analyzed. Expand
The correlation between intestinal dysbiosis and the development of ankylosing spondylitis.
TLDR
The possible correlation between intestinal dysbiosis and AS development from aspects including genetic factor HLA-B27, mucosal immune responses and the depression accompanying AS is discussed. Expand
The gut-joint axis in spondyloarthritis: immunological, microbial, and clinical insights.
TLDR
This knowledge has practical implications in predicting the likelihood of IBD development in SpA or presence of coincident SpA-IBD, uncovering novel therapeutic targets, and redesigning currently approved treatments. Expand
Ankylosing spondylitis: etiology, pathogenesis, and treatments
TLDR
The current study reviewed the etiology and pathogenesis of AS, including genome-wide association studies and cytokine pathways, and summarized the current pharmaceutical and surgical treatment with a discussion of future potential therapies. Expand
The interaction between host genetics and the microbiome in the pathogenesis of spondyloarthropathies
TLDR
Intestinal barrier function, deletional tolerance, Th17 signature response, and endoplasmic reticulum stress pathways have been recently linked to SpA, indicating dysregulated immune responses to the gut microbiota and an altered microbial community structure are shared features of SpA. Expand
Perspectives on the Genetic Associations of Ankylosing Spondylitis
TLDR
Polygenic risk scores (using all the known genetic associations with AS) can be effective for the diagnosis of AS, particularly where there is a relatively high pre-test probability of AS. Expand
Immunological Basis of Inflammatory Arthritides
TLDR
In genetically predisposed individuals, the initial immunologic events in the pathogenesis of seropositive RA occur in the lungs, where smoking triggers citrullination of lung proteins and asymptomatic production of ACPA (preclinical RA). Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 73 REFERENCES
Intestinal Dysbiosis in Ankylosing Spondylitis
Objective. Ankylosing spondylitis (AS) is a common, highly heritable immune-mediated arthropathy that occurs in genetically susceptible individuals exposed to an unknown but likely ubiquitousExpand
Macrophage phenotype in the subclinical gut inflammation of patients with ankylosing spondylitis.
TLDR
The absence of CD14(+) macrophages together with the expansion of resolution phase and M2macrophages is the immunological signature of subclinical ileal inflammation in AS. Expand
Long-term evolution of gut inflammation in patients with spondyloarthropathy.
TLDR
The evolution of the intestinal inflammation observed in patients with SpA supports the etiopathogenetic role of the gut in SpA and has a beneficial effect on articular activity by controlling gut inflammation, but it cannot prevent evolution to overt IBD. Expand
Intestinal permeability in patients with ankylosing spondylitis and their healthy relatives.
TLDR
The findings suggest that the increase in gut permeability in AS patients and their relatives is a primary defect and may be an aetiologic factor in this disease. Expand
Ileocolonoscopy in seronegative spondylarthropathy.
TLDR
This study identified a group of patients with seronegative spondylarthropathy which, even in the absence of gastrointestinal symptoms, showed evidence of gut inflammation, probably inducing an increased gut permeability with transgression of the oral tolerance and absorption of provocative antigens into the circulation. Expand
OP0205 Gut Dysbiosis in Patients with HLA-B27+ Ankylosing Spondylitis is Associated with Ileitis, Down-Regulation of Tight Junction Proteins, Increased Serum Levels of LPS and Monocytes Anergy
TLDR
Bacterial ileitis, accompanied by damaged intestinal mucosal barrier, characterizes As patients and i-FABP and LPS are increased in the peripheral blood of AS patients and associated with the down-regulation of LPS co-receptor CD14 and with an anergic monocyte phenotype. Expand
Altered microbiota associated with abnormal humoral immune responses to commensal organisms in enthesitis-related arthritis
TLDR
The abundance of F. prausnitzii in the stool among patients with ERA is reduced compared to controls, and Bacteroides and A. muciniphila are identified as associative agents in subsets of ERA patients, which may contribute to disease. Expand
Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis.
TLDR
It is indicated that overexpression of IL-23, but not IL-17, is a pivotal feature of subclinical gut inflammation in AS, providing a pathophysiologic significance to the reported association between IL- 23 receptor polymorphisms and intestinal inflammation. Expand
Spondyloarthropathy: interleukin 23 and disease modification
TLDR
The emerging centrality of interleukin 23 in spondyloarthropathy was sought, and the exact mechanism by which this cytokine drives disease was identified, to explain another feature of these conditions: specifi cally, the tendency of disease to localise to the interface between tendons and bone—the entheses. Expand
Bowel permeability and CD45RO expression on circulating CD20+ B cells in patients with ankylosing spondylitis and their relatives.
TLDR
Patients with AS have altered small intestinal, but not gastric, permeability and increased CD20+CD45RO+ expression suggests increased antigen exposure, which may be related to previous or current intestinal permeability abnormalities. Expand
...
1
2
3
4
5
...